*  Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer - Full Text View -...
OBJECTIVES:. I. Determine the maximum tolerated doses of a rebeccamycin analogue and cisplatin with or without filgrastim (G-CSF) in patients with advanced malignancies.. II. Determine the qualitative and quantitative toxicities of these regimens in these patients.. III. Determine if the pharmacokinetics of a rebeccamycin analogue are affected by cisplatin and if there are sequence dependent pharmacokinetic effects.. IV. Assess any antitumor effects of this regimen in these patients.. OUTLINE: This is a dose-escalation, multicenter study of a rebeccamycin analogue and cisplatin.. Part I (previously untreated or minimally pretreated patients): The first patient of each cohort receives cisplatin IV over 1 hour followed 2 hours later by a rebeccamycin analogue IV over 1 hour on day 1. The second patient in the same cohort receives the same drugs in the reverse order. The drug sequence for each additional patient within the same cohort is alternated with reference to the preceding patient. During ...
  https://clinicaltrials.gov/ct2/show/NCT00004189
*  Isoflavone-7-O-beta-glucoside 6''-O-maloniltransferasi - Wikipedia
La isoflavone-7-O-beta-glucoside 6''-O-maloniltransferasi è un enzima appartenente alla classe delle transferasi, che catalizza la seguente reazione: malonil-CoA + biocianina A 7-O-β-D-glucoside ⇄ CoA + biocianina A 7-O-(6-O-malonil-β-D-glucoside) Anche la posizione 6 del residuo glucosidico della formononetina può agire da accettore. Anche altri 7-O-glucosidi di isoflavoni, flavoni e flavonoli possono esserlo, ma più lentamente. Matern, U., Feser, C. and Hammer, D., Further characterization and regulation of malonyl-coenzyme A: flavonoid glucoside malonyltransferases from parsley cell suspension cultures, in Arch. Biochem. Biophys., vol. 226, 1983, pp. 206-217, Entrez PubMed 6639051. Koester, J., Bussmann, R. and Barz, W., Malonyl-coenzyme A:isoflavone 7-O-glucoside-6′′-O-malonyltransferase from roots of chick pea (Cicer arietinum L.), in Arch. Biochem. Biophys., vol. 234, 1984, pp. 513-521, Entrez PubMed 6497385 ...
  https://it.wikipedia.org/wiki/Isoflavone-7-O-beta-glucoside_6''-O-maloniltransferasi
*  3S)-3-acetamido-4-amino-4-oxobutanoic acid 60803-67-0 MSDS, Safety Technical Specifications MSDS
(3S)-3-acetamido-4-amino-4-oxobutanoic acid 60803-67-0 MSDS report, (3S)-3-acetamido-4-amino-4-oxobutanoic acid MSDS safety technical specifications search, (3S)-3-acetamido-4-amino-4-oxobutanoic acid safety information specifications ect.
  http://www.molbase.com/en/msds_60803-67-0-moldata-52043.html
*  Glucoside synonyms, glucoside antonyms - FreeThesaurus.com
Synonyms for glucoside in Free Thesaurus. Antonyms for glucoside. 3 words related to glucoside: glycoside, amygdalin, saponin. What are synonyms for glucoside?
  http://www.freethesaurus.com/glucoside
*  Ipragliflozin - Wikipedia
Ipragliflozin (INN, trade names Suglat) is a pharmaceutical drug for treatment of type 2 diabetes. Ipragliflozin, jointly developed by Astellas Pharma and Kotobuki Pharmaceutical, was approved in Japan on January 17, 2014. Ipragliflozin is a Sodium/glucose cotransporter 2 (SGLT2) inhibitor (gliflozin). These membrane proteins are on the cell surface and transfer glucose into the cells. SGLT2 is one subtype of SGLTs and plays a key role in the reuptake of glucose in the proximal tubule of the kidneys. Ipragliflozin reduces blood glucose levels by inhibiting the reuptake of glucose by selectively inhibiting SGLT2. The efficacy and safety of ipragliflozin were both observed in a Phase III study in monotherapy and clinical studies used in combination with other hypoglycemic agents (6 types) in Japan. One placebo-controlled, double-blind study was carried out at 18 different sites in Korea and 12 in Taiwan. Patients were above 20 and had type 2 diabetes for atlas 12 weeks. They were given an 8-week ...
  https://en.wikipedia.org/wiki/Ipragliflozin
*  Lauryl glucoside - Wikipedia
Lauryl glucoside is a surfactant used in cosmetics. It is a glycoside produced from glucose and lauryl alcohol. Decyl glucoside Octyl glucoside n-Dodecyl β-D-glucopyranoside at Sigma- ...
  https://en.wikipedia.org/wiki/Lauryl_glucoside
*  GW24-e2172 Effects of salidroside on myocardial acute exhaustive exercise injury on MAPK pathway | Heart
Methods Healthy SD 40 male rats were randomly divided into four groups (n = 10): control group, acute exhaustived exercise group, salidroside group, salidroside and acute exhaustived exercise group. The control and acute exhaustive exercise group were given 0.9%Nacl (12ml·kg-1·d-1) for 14 consecutive days. The salidroside group and salidroside and acute exhaustived exercise group were given salidroside (24mg·kg-1·d-1)for 14 consecutive days. Acute exhaustive rat model were prepared by exhaustive swimming in pool. Western blot was used to detect the expression of ERK, p- ERK, P38and p-P38protein.. ...
  http://heart.bmj.com/content/99/Suppl_3/A37.1
*  Dapagliflozin - Wikipedia
Dapagliflozin (INN, USAN, trade name Farxiga /fɑːrˈsiːɡə/ far-SEE-gə in the U.S. and Forxiga in the EU and Russia) is a drug of the gliflozin class, used to treat type 2 diabetes. It was developed by Bristol-Myers Squibb in partnership with AstraZeneca. In July 2011 a U.S. Food and Drug Administration (FDA) endocrinologic and metabolic drugs advisory committee recommended against approval until more data were available. The FDA approved dapagliflozin on January 8, 2014 for glycemic control, along with diet and exercise, in adults with type 2 diabetes. In 2012, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion on the drug. It is now marketed in a number of European countries. The FDA approved the combination product dapagliflozin and metformin hydrochloride extended-release, called Xigduo XR, in November 2014. In Feb 2017 the FDA approved a once-daily combination of dapagliflozin 10 mg and saxagliptin 5 mg, as Qtern. Since ...
  https://en.wikipedia.org/wiki/Dapagliflozin
*  Molecules | Free Full-Text | Two New Cyanogenic Glucosides from the Leaves of Hydrangea macrophylla
Chemical investigation of the ethanol extract of the aerial parts of Hydrangea macrophylla collected in the Sichuan Province of China resulted in the isolation of two new cyanogenic glucosides. Their structures were elucidated as [(2R)-2-(b-D-glucopyranosyloxy)-2-(3,4-dimethoxy-phenyl)] acetonitrile (1) and {(2R)-2-[a-D-glucopyranosyl(1®6)b-D-glucopyranosyloxy]-2-(3-hydroxy-4-methoxy-phenyl)}acetonitrile (2) on the basis of extensive spectroscopic analysis (1D, 2D NMR and HRESIMS) and chemical studies.
  http://www.mdpi.com/1420-3049/17/5/5396
*  A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients...
The aim of this study is to investigate the efficacy and safety of two doses (high and low) of empagliflozin as add-on therapy to metformin in patients with type 2 diabetes mellitus (T2DM) and insufficient glycaemic control. Both doses may be given once daily or split to a twice daily dosage. This results in 4 different dosage regimens of empagliflozin (high dose once daily or split vs. low dose once daily or split). This is done to evaluate whether a twice daily dose regimen of empagliflozin results in a loss of efficacy relative to once daily dosing when given on top of metformin background therapy ...
  https://clinicaltrials.gov/ct2/show/NCT01649297?term=%22Type+2+Diabetes%22&lup_s=10%2F08%2F2013&lup_d=14&show_rss=Y&sel_rss=mod14
*  A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients...
The aim of this study is to investigate the efficacy and safety of two doses (high and low) of empagliflozin as add-on therapy to metformin in patients with type 2 diabetes mellitus (T2DM) and insufficient glycaemic control. Both doses may be given once daily or split to a twice daily dosage. This results in 4 different dosage regimens of empagliflozin (high dose once daily or split vs. low dose once daily or split). This is done to evaluate whether a twice daily dose regimen of empagliflozin results in a loss of efficacy relative to once daily dosing when given on top of metformin background therapy ...
  https://clinicaltrials.gov/ct2/show/record/NCT01649297?term=%22Type+2+Diabetes%22&lup_s=08%2F31%2F2013&lup_d=14&show_rss=Y&sel_rss=mod14
*  A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients...
The aim of this study is to investigate the efficacy and safety of two doses (high and low) of empagliflozin as add-on therapy to metformin in patients with type 2 diabetes mellitus (T2DM) and insufficient glycaemic control. Both doses may be given once daily or split to a twice daily dosage. This results in 4 different dosage regimens of empagliflozin (high dose once daily or split vs. low dose once daily or split). This is done to evaluate whether a twice daily dose regimen of empagliflozin results in a loss of efficacy relative to once daily dosing when given on top of metformin background therapy ...
  https://clinicaltrials.gov/ct2/show/study/NCT01649297?show_rss=Y&sel_rss=mod14&show_locs=Y
*  A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients...
The aim of this study is to investigate the efficacy and safety of two doses (high and low) of empagliflozin as add-on therapy to metformin in patients with type 2 diabetes mellitus (T2DM) and insufficient glycaemic control. Both doses may be given once daily or split to a twice daily dosage. This results in 4 different dosage regimens of empagliflozin (high dose once daily or split vs. low dose once daily or split). This is done to evaluate whether a twice daily dose regimen of empagliflozin results in a loss of efficacy relative to once daily dosing when given on top of metformin background therapy ...
  https://clinicaltrials.gov/ct2/show/study/NCT01649297?term=%22Type+2+Diabetes%22&lup_s=11%2F06%2F2013&lup_d=14&show_rss=Y&sel_rss=mod14&show_locs=Y
*  Cyanidin 3-glucoside | KUROMANIN
Cyanidin 3-glucoside Cyanidin 3-glucoside (C3G) which belongs to Anthocyanin is more contained in Black soybean seed coats than in wine or blueberry. The
  http://sozai-kinou.co.jp/en/cyanidin/
*  GFIT result for T00711
tr:B2VKZ2_ERWT9] bglA; BglA protein, 6-phospho-beta-glucosidase (involved in beta-glucoside utilization); K01223 6-phospho-beta-glucosidase [EC:3.2.1.86] ...
  http://www.kegg.jp/ssdb-bin/www_ssget?eta:ETA_04790
*  4-((4-(Aminosulfonyl)phenyl)amino)-4-oxobutanoic acid monoammonium salt | C10H15N3O5S - PubChem
4-((4-(Aminosulfonyl)phenyl)amino)-4-oxobutanoic acid monoammonium salt | C10H15N3O5S | CID 60587 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.
  https://pubchem.ncbi.nlm.nih.gov/compound/60587
*  4-[(3-chloro-4-methylphenyl)amino]-4-oxobutanoic acid | C11H12ClNO3 - PubChem
4-[(3-chloro-4-methylphenyl)amino]-4-oxobutanoic acid | C11H12ClNO3 | CID 306263 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.
  https://pubchem.ncbi.nlm.nih.gov/compound/306263
*  4-[(2-Fluoro-5-methylphenyl)amino]-4-oxobutanoic acid - Alfa Chemistry
4-[(2-Fluoro-5-methylphenyl)amino]-4-oxobutanoic acid/AFI904766638 can be provided in Alfa Chemistry. We are dedicated to provide our customers the best products and services.
  http://www.alfa-chemistry.com/cas_904766-63-8.htm
*  Canagliflozin : usage, side effects, expert advice and canagliflozin based medicines | 1mg
Canagliflozin is used in the treatment of type 2 diabetes.get complete information about canagliflozin including usage, side effects, drug interaction, expert advice along with medicines associated with canagliflozin at 1mg.com
  https://www.1mg.com/generics/canagliflozin-212970
*  The Ordinary Ascorbyl Glucoside Solution 12%
Get radiant results when you use The Ordinary Ascorbyl Glucoside Solution 12%, a topical vitamin C treatment that brightens dull skin tones. For those looking for a visibly brighter complexion, the Ascorbyl Glucoside Solution 12% is a light ser
  https://www.escentual.com/the-ordinary/theordinary005/
*  Feature Story | More Clinical Insights From ESC 2017 Congress - American College of Cardiology
Another analysis from EMPA-REG OUTCOME showed that empagliflozin added to standard of care was associated with substantial reductions in cardiovascular death and all-cause mortality as well as hospitalization for HF in patients with T2D who'd had a CABG. The magnitude of the benefits in the CABG subgroup was at least as large as that in the main trial, yielding important translational implications for secondary prevention following CABG, said presenter Subodh Verma, MD, PhD.. In 1,738 patients with a prior CABG (1,175 patients taking empagliflozin), the composite of cardiovascular death, non-fatal myocardial infarction (MI) and stroke (3-point MACE) was 10.6 percent in the pooled empagliflozin group vs. 13.3 percent in the placebo group. With empagliflozin vs. placebo, the incidence of all-cause mortality was 5.1 percent vs. 8.9 percent and of cardiovascular death was 3.0 percent vs. 5.7 percent. For stroke, the incidence was 3.3 percent vs. 2.7 percent with empagliflozin vs. placebo, and for MI ...
  http://www.acc.org/latest-in-cardiology/articles/2017/09/14/09/42/more-clinical-insights-from-esc-2017-congress
*  Plus it
Objective: Dapagliflozin, a novel inhibitor of renal sodium-glucose co-transporter 2, allows an insulin-independent approach to improve type 2 diabetes mellitus (T2DM) hyperglycemia. This multipledose study evaluated safety and efficacy of dapagliflozin in T2DM patients.. Research Design and Methods: T2DM patients were randomized to one of five dapagliflozin doses, metformin XR, or placebo for 12 weeks. The primary objective compared mean change from baseline in glycated hemoglobin (A1C). Other objectives included change in fasting plasma glucose (FPG), weight, adverse events, and laboratory measurements.. Results: After 12 weeks, dapagliflozin induced moderate glucosuria (52-85 g urinary glucose/day) and demonstrated significant glycemic improvements versus placebo (ΔA1C, −0.55 to −0.90%; ΔFPG, −16 to −31 mg/dl). Weight loss versus placebo was −1.3 to −2.0 kg. There was no change in renal function. Serum uric acid decreased, serum magnesium increased, serum phosphate increased at ...
  http://care.diabetesjournals.org/content/early/2008/12/29/dc08-1863
*  Pyridoxine-4-thiol | C8H11NO2S - PubChem
Pyridoxine-4-thiol | C8H11NO2S | CID 83834 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.
  https://pubchem.ncbi.nlm.nih.gov/compound/Pyridoxine-4-thiol
*  pyridoxine-3-4-dipalmitate | VWR
Learn more about pyridoxine-3-4-dipalmitate. We enable science by offering product choice, services, process excellence and our people make it happen.
  https://us.vwr.com/store/product/20666885/pyridoxine-3-4-dipalmitate